Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Genetic risk profiles could change how we monitor Barrett's esophagus

NCT ID NCT07455422

Knowledge-focused Sponsor: University Hospital, Antwerp Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether sharing genetic risk information with Barrett's esophagus patients can improve their quality of life and reduce cancer worry. Researchers will collect tissue samples and use genetic analysis to create risk profiles. Half of the 266 participants will learn their risk profile, while the other half will not. The goal is to see if this approach leads to better, more cost-effective surveillance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to more personalized and cost-effective surveillance for Barrett's esophagus patients, reducing unnecessary procedures and anxiety.
What could go wrong
This is an early-stage observational study, not testing a treatment. The risk model may not prove accurate enough to change practice, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 266 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with known BE undergoing endoscopy for possible treatment by EMR or ESD due to suspicion of T1 oesophageal Barrett cancer * Capable of receiving informed consent and of giving permission * Age 18 and upward Exclusion Criteria: * Patients with current known malignancy of the gastrointestinal tract other than the esophageal lesion * Patients refusing randomization and corresponding follow-up intervals based on biomarker profile * Patients with severe co-morbidity that prohibits endoscopic therapy under sedation or conscious sedation (such as severe cardiac or pulmonary disease) * Esophageal varices * Uncontrollable coagulation disorders * Undergoing/planned chemotherapy or immunotherapy or received chemotherapy \< 6 months prior to endoscopy * Undergoing/planned radiotherapy within the esophageal region or received radiotherapy \< 6 months prior to endoscopy * WHO score \>3

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenocarcinoma - gej are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenocarcinoma Barrett adenocarcinoma Barrett esophagus digestive system cancer esophageal adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenocarcinoma - gej Barrett esophagus Barrett esophagus adenocarcinoma Gastroenterological cancer Gastroenterology

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Delta

    Roeselare, Belgium, 8800, Belgium

  • Antwerp University Hospital

    Edegem, Antwerpen, 2650, Belgium

  • CHU LILLE - Centre Hospitalier Universitaire de Lille

    Lille, 59000, France

  • Ghent University Hospital (UZ Gent)

    Ghent, Belgium, 9000, Belgium

  • IRCCS Ospedale San Raffaele

    Milan, Milano, 20132, Italy

  • Karolinska University Hospital

    Solna, SE-171 76, Sweden

  • Rigshospitalet

    Copenhagen, 2100, Denmark

  • Sint-Augustinus Hospital (ZAS)

    Wilrijk, Antwerpen, 2610, Belgium

  • St James's Hospital

    Dublin, D08 NHY1, Ireland

  • University Hospital Leipzig

    Leipzig, Leipzig, 04103, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.